Influence of dilution on arterial-phase artifacts and signal intensity on gadoxetic acid–enhanced liver MRI

Sarah Poetter-Lang¹ · Gregor O. Dovjak¹ · Alina Messner¹ · Raphael Ambros¹ · Stephan H. Polanec¹ · Pascal A. Baltzer¹ · Antonia Kristic¹ · Alexander Herold¹ · Jacqueline C. Hodge¹ · Michael Weber¹ · Nina Bastati¹ · Ahmed Ba-Ssalamah¹

Received: 7 March 2022 / Revised: 17 June 2022 / Accepted: 22 June 2022 / Published online: 27 July 2022
© The Author(s) 2022

Abstract

Objectives To investigate the effect of saline-diluted gadoxetic acid, done for arterial-phase (AP) artifact reduction, on signal intensity (SI), and hence focal lesion conspicuity on MR imaging.

Methods We retrospectively examined 112 patients who each had at least two serial gadoxetic acid–enhanced liver MRIs performed at 1 ml/s, first with non-diluted (ND), then with 1:1 saline-diluted (D) contrast. Two blinded readers independently analyzed the artifacts and graded dynamic images using a 5-point scale. The absolute SI of liver parenchyma, focal liver lesions (if present), aorta, and portal vein at the level of the celiac trunk and the SI of the paraspinal muscle were measured in all phases. The signal-to-norm (SI\textsubscript{Norm}) of the vascular structures, hepatic parenchyma and focal lesions, and the contrast-to-norm (C\textsubscript{Norm}) of focal liver lesions were calculated.

Results AP artifacts were significantly reduced with dilution. Mean absolute contrast-enhanced liver SI was significantly higher on the D exams compared to the ND exams. Likewise, SI\textsubscript{Norm} of liver parenchyma was significantly higher in all contrast-enhanced phases except transitional phase on the D exams. SI\textsubscript{Norm} values in the AP for the aorta and in the PVP for portal vein were significantly higher on the diluted exams. The C\textsubscript{Norm} was not significantly different between ND and D exams for lesions in any imaging phase. The interclass correlation coefficient was excellent (0.89).

Conclusion Gadoxetic acid dilution injected at 1 ml/s produces images with significantly fewer AP artifacts but no significant loss in SI\textsubscript{Norm} or C\textsubscript{Norm} compared to standard non-diluted images.

Keywords Liver · Magnetic resonance imaging · Gadolinium ethoxybenzyl DTPA · Artifacts · Signal intensity

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| Abs          | Absolute   |
| AP           | Arterial phase |
| BMI          | Body mass index |
| C\textsubscript{Norm} | Contrast-to-norm ratio |

D Diluted imaging protocol
DTPA Diethylenetriamine penta-acetic acid
FOV Field of view
HASTE Half-Fourier single-shot turbo spin-echo
HBP Hepatobiliary phase
ICC Intraclass correlation coefficient
IV Intravenous
MRI Magnetic resonance imaging
ND Non-diluted imaging protocol
PACS Picture archiving and communication system
ROI Region of interest

© Ahmed Ba-Ssalamah
ahmed.ba-ssalamah@meduniwien.ac.at

¹ Department of Biomedical Imaging and Image-Guided Therapy, General Hospital of Vienna (AKH), Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria
Introduction

Gadoxetic acid (gadolinium ethoxybenzyl DTPA)–enhanced magnetic resonance imaging (MRI) is increasingly used for detection and characterization of focal liver lesions [1, 2]. However, one of gadoxetic acid’s major drawbacks is arterial-phase (AP) artifacts which may degrade image quality, limiting diagnosis of focal liver lesions [3–5].

Two types of AP artifacts have been reported during gadoxetic acid–enhanced MR imaging. The first is transient severe motion (TSM) due to acute fleeting elevation of peak gadoxetic acid blood plasma concentration and is associated with acute transient dyspnea [6, 7]. The second, truncation artifacts, may be related to the relatively rapid disappearance of contrast from the imaging field. Both small volumes (≤ 10 ml) and recommended injection rates (e.g., 2 ml/s) yield a compact contrast bolus and rapid changes in intravascular gadoxetic acid concentration during k-space data acquisition [8, 9].

To overcome these artifacts, several strategies have been developed [9–15]. Two of the most promising techniques are saline dilution of gadoxetic acid at 1:1 and slow injection rate of 1 ml/s. Both are off-label use as the suggested dose is undiluted 0.1 mmol/kg at 2 ml/s. Both stretch the bolus length, and lower the peak plasma gadoxetic acid concentration during the arterial phase [7, 14, 16]. In turn, lower peak plasma concentrations may fall below the threshold that triggers central chemoreceptors, thus preventing hyperventilation and minimizing TSM, as suggested by Polance et al [7]. Furthermore, the prolonged arterial phase improved uniformity of contrast bolus during the acquisition allowing more homogeneous filling of central k-space. Therefore, diluted gadoxetic acid injected at 1 ml/s, following a test bolus tracking technique, has been shown to reduce TSM artifacts significantly [7]. However, we wondered if decreasing the peak contrast concentration through dilution and slower injection rate would also cause SI loss yielding suboptimal images with low signal or contrast values, impairing focal liver lesion detection, the main diagnostic task.

Thus, our primary aim was to investigate the effect of dilution and slow injection rate of 1 ml/s on quantitative differences in absolute signal intensity, signal-to-norm, and contrast-to-norm on MR images in the arterial, portal venous, transitional, and 20-min hepatobiliary (HB) phases. Secondly, we also evaluated the non-diluted (ND) and saline-diluted (D) images post-intravenous gadoxetic acid for AP artifacts.

Materials and methods

Patients

For this single-center retrospective study, designed according to STROBE (Strengthening the Reporting of Observational Studies in Epidemiology), our institutional ethics review board approved the data collection and analysis and waived the requirement for informed consent. A search in our picture archiving and communication system (PACS) database identified 4130 consecutive liver MRIs performed for known or suspected liver or pancreaticobiliary diseases between December 2010 and July 2017 (Fig. 1). One hundred twenty-one (n = 121) patients had undergone at least one non-diluted (ND) between December 2010 and 2014 and one saline-diluted (D) between January 2015 and July 2017 power-injected gadoxetic acid–enhanced MRI, at 1 ml/s with identical exam parameters. Patients were excluded if they had undergone liver transplantation between the two MRIs (n = 1). We further excluded one patient that had been studied before the software update. Seven additional patients were excluded because they had artifacts in all sequences, including non-contrast images. If patients had several serial MRI exams, we took the most recent non-diluted MRI and compared with

**Fig. 1** Flowchart of the exclusion criteria yielding eligible patients. MRI = magnetic resonance imaging
the first diluted MRI exam, i.e., we took the two MRIs that were closest in proximity to one another.

**MR examination protocol**

All patients underwent a 3 Tesla liver MRI (Magnetom, Trio Tim, Siemens Medical Systems) using a combined six-element, phased-array abdominal coil and a fixed spine coil to improve SNR. Unenhanced and contrast-enhanced imaging was performed using fat-suppressed T1-weighted three-dimensional gradient-echo volumetric interpolated breath-hold examination (VIBE) sequence. VIBE imaging parameters for both the diluted and non-diluted patients were as follows: TR 2.67 ms, TE 0.97 ms, phase direction AP, and flip angle 13°. Depending upon the patient size, slice thickness (1.7 to 2 mm), matrix size (288 × 168 to 512 × 384), FOV (380 to 430 mm), and number of slices (90 to 120) varied. Parallel imaging with an acceleration factor of two was used in both groups. Matrix and slice thickness given are for the re-construction using zero interpolation. The prescan normalization filter provided by the vendor was activated in all sequences to homogenize the SI.

An intravenous (IV) bolus of gadoxetic acid was administered at a dosage of 0.025 mmol/kg body weight (0.1 ml/kg body weight) through a 20- to 22-gauge antebrachial venous catheter. Dynamic images were obtained at t-peak plus 5 s (arterial), 70 s (portal venous), 300 s (transitional phase), and 20 min, i.e., hepatobiliary phase (HBP) with the identical parameters used for unenhanced sequence; t-peak determination is described below. Our k-space ordering was sequential. The acquisition time per sequence ranged from 14 to 20 s, depending on patient size. The exam protocol also included axial in- and opposed-phase T1-weighted images, T2-weighted HASTE, and diffusion-weighted images. There was one software upgrade during the 7-year study period, which affected a single patient that was subsequently excluded from the cohort. Scanner and imaging parameters for both groups (D and ND) were unaltered.

**Contrast media injection techniques**

All test doses were 0.5 ml of gadoxetic acid injected at 1 ml/s; the bolus was flushed with 25 ml saline via a power injector (Spectris Solaris, MR; Medrad Europe) at the same flow rate. During the test injection, T1-weighted GRE 2D axial images were obtained at one frame/s for 60 s, thus capturing multiple arterial, mixed, and portal venous phase images during gadoxetic acid’s passage through the aorta. Based upon these preliminary images, the post-injection time in which the SI of the aorta at the level of the celiac artery appeared highest was selected as the time to peak aortic enhancement (t-peak) for that patient. Next, 0.025 mmol/kg body weight of gadoxetic acid was administered as an IV bolus at 1 ml/s, ND (from December 2010 to December 2014). Aiming to reduce artifacts, we started administering an IV bolus of 1:1 saline-diluted (D) gadoxetic acid in January 2015, administered as an IV bolus at the same rate of 1 ml/s. The duration of contrast injection depended upon the contrast volume. For example, a non-diluted 10-ml volume required 10 s, whereas when diluted, the 20 ml volume took 20 s. Then, dynamic imaging was performed as described above, with arterial-phase imaging initiated at the individual patient’s t-peak, as determined by the test injection plus 5 s. We used an automated voice recording to give patients breathing instructions.

**Image analysis**

Dynamic T1-weighted sequences (unenhanced, arterial, portal venous, transitional, and 20-min HB phases) were reviewed by two readers (G.D. and S.P.) independently, each with at least 5 years of experience in liver MRI, and the presence of artifacts was graded on a 5-point scale, as described before [17]: (1) no artifacts, (2) minimal artifacts, without diagnostic effect, (3) moderate artifacts, with minimal diagnostic effect, (4) marked artifacts, with significant diagnostic effect, and (5) severe artifacts, non-diagnostic. Seven patients with artifacts in all sequences were excluded on the assumption that these artifacts were not solely injection-related artifacts. AP artifacts were defined as a score ≥ 4 during the arterial phase [4]. To reach the final artifact score, the scores of readers 1 and 2 were averaged and rounded up.

Next, quantitative image analysis was performed by the same two readers (G.D. and S.P.) independently and blinded to the contrast injection method. Images were randomly reviewed on a dedicated PACS workstation. Quantitative signal intensity (SI) measurements were acquired by drawing regions of interest (ROI) at the level of the celiac trunk. SI was recorded, placing the ROI as follows [18]: for the aorta, main portal vein ≥ 0.5 cm²; for the right anterior, right posterior, left medial, and left lateral liver segments ≥ 2 cm²; and for paraspinal muscle 1–2 cm². Finally, for patients with visible liver lesions ≥ 1 cm², deemed comparable between the two exams, a ROIs was drawn to encompass the largest lesion in its entirety (Fig. 2). For patients with comparable lesions of more than one etiology, the largest was selected for SI measurements. No ROIs were placed in hepatic parenchyma containing large vessels. The same ROIs were chosen and copied to identical positions in all imaging phases (unenhanced, arterial, portal venous, transitional, and HB) for each patient. To normalize the obtained SI values, we chose to use the SI of the paraspinal muscle as a reference to calculate the signal-to-norm ratio (SI_{Norm}) [19]. The SI_{Norm} was calculated for each ROI using the equation: $SI_{Norm}(i) = \frac{SI_{ref}}{SI_{musc}}$, where $i$ is the tissue being measured. Lastly, the contrast-to-norm ratio ($C_{Norm}$), referring to focal liver lesion conspicuity, was calculated using the equation: $C_{Norm} = \frac{abs(SI_{Norm}(\text{liver}) - SI_{Norm}(\text{lesion}))}{abs(SI_{Norm}(\text{liver}))}$, on unenhanced, arterial, portal venous, transitional, and HB phases, respectively. The absolute difference
was chosen to obtain a value that represents the visible difference between liver parenchyma and focal lesion, whether hypointense or hyperintense.

**Statistical analysis**

For this study, our null hypothesis was that diluted exams, performed for AP artifact reduction, do not differ in the SI and SI\textsubscript{Norm} of the vascular structures and liver parenchyma as well as \( C_{\text{Norm}} \) of focal liver lesions. Our alternative hypothesis was that dilution would lead to SI, SI\textsubscript{Norm}, and \( C_{\text{Norm}} \) decrease or increase in comparison to ND scans. All statistical analyses were performed with commercially available software. For data collection and management, an Excel (Microsoft Corporation) spreadsheet was used. The statistical analysis was performed with SPSS Statistics version 26 (IBM).

Patient characteristics that were continuous variables (e.g., patient age, BMI) were summarized with means and standard deviation. Categorical variables (e.g., patient gender, presence of ascites, and/or cirrhosis) were summarized with counts and percentages. The inter-rater variability was assessed by two-way mixed intraclass correlation coefficient (ICC) with an absolute agreement for quantitative SI differences and using Cohen’s kappa (\( \kappa \)) coefficient for qualitative artifacts interpretation. We performed a paired \( t \)-test for comparison of the means of ND and D exams to assess the effect of dilution on SI and SI\textsubscript{Norm}. To compare \( C_{\text{Norm}} \) of focal liver lesions, only subgroups with \( n \geq 10 \) were chosen. To compare signal intensities between the different artifact grade groups, Welch’s corrected one-way ANOVAs
were used for the ND and D groups separately, grouping grades 4 and 5 because of their small number. As the design of this study was not confirmatory, the beta error (sensitivity to find statistical significance) is considered worse than the alpha error (specificity of statistical significances). Therefore, no formal correction for multiple testing was used. Related samples Wilcoxon’s signed-rank test was used to compare artifact grades between D and ND. Fisher’s exact test was used to compare the sizes of groups with AP artifacts with those without AP artifacts between ND and D exams. Values of $p < 0.05$ were considered statistically significant.

## Results

The demographics of the 112 study patients (50 female and 62 male) are listed in Table 1. The mean time interval between the two MRI examinations was 746 days (range 199–1828 days). All MRIs were performed with the same scanner, software, and examination protocol. The sole exception was contrast media application, at 1 ml/s, which was either diluted or non-diluted. The mean patient age at the first MRI exam was 54.8 years (21–85 years) and the mean BMI was 25.3 kg/m$^2$ (17.7–35.5 kg/m$^2$). At follow-up exam, the mean age was 56.9 (23–85 years) and mean BMI 25.2 kg/m$^2$ (17.5–39.1 kg/m$^2$, $p = 0.922$). For the disease severity in cirrhotic patients, there was no significant interval change in the Child-Pugh score (5.85 versus 6.04, $p = 0.612$) and MELD score (6.05 versus 7.35, $p = 0.218$). Regarding renal function, there was no significant change in the interim for GFR (97.67 vs 94.34, $p = 0.37$). No cardiac events were noted in the medical record for any patient during the study period.

### Signal intensity measurements

On the unenhanced liver MRIs, there were no statistically significant differences in SI and $SI_{Norm}$ between the ND and D exams in the aorta, liver, PV, or lesion (Tables 2 and 3). The mean absolute liver parenchyma SI was significantly higher for the D exams compared to the ND exams, on arterial, portal venous, transitional, and HB phases ($p = 0.012$, $p = 0.002$, $p = 0.019$, and $p < 0.001$, respectively) (Table 2). Furthermore, mean liver $SI_{Norm}$ was significantly higher on the D exams compared to the ND exams in the arterial, portal venous, and hepatobiliary phases ($p = 0.002$, $p = 0.010$, and $p < 0.001$, respectively) (Table 3). The greatest difference was observed in the HBP. Furthermore, the mean $SI_{Norm}$ of the aorta in the AP and of the portal vein in the portal venous phase was significantly higher in the D exams ($p = 0.005$ and $p = 0.035$), respectively (Table 3).

There were 68 (60.7%) focal liver lesions on the ND exams of the 112 patients (Table 1), 48.5% of which were excluded due to interim change between ND and D exams. The etiology of the 35 comparable (51.5%) lesions included 12 FNH (34.3%), 11 metastases (31.4%), 5 cirrhotic nodules (cirrhotic nodules, i.e., LIRADS 3–5 lesions (14.3%), 4 adenomas (11.4%), and 3 hemangiomas (8.6%). There was no significant difference in the $C_{Norm}$ of all lesions combined for D versus ND exams (all phases $p > 0.05$). Evaluation of lesion subtype, when $n \geq 10$ (i.e., FNH and metastases), also revealed no significant difference in $C_{Norm}$ between the ND and D exams (all phases $p > 0.05$) (Table 4, Fig. 4).

### Influence of the artifacts on signal intensities

Arterial-phase artifacts did not have a significant influence on the signal intensity of liver parenchyma on the ND ($p = 0.627$) and on D ($p = 0.644$) exams. The vast majority of the arterial-phase artifacts in our cohort were TSM. No truncation artifacts affected diagnostic efficacy. To assess the effect of artifacts on lesion visibility, aside from $C_{Norm}$, we looked at the visibility of lesions

---

**Table 1** Demographic patient data. One HCC (LIRADS 3-5 lesion) and one metastasis developed in between scans in patients where no lesion was reported priorly. One adenoma developed in a treated lesion. One patient with a treated lesion developed recurrent HCC. Seven HCC lesions and eight metastases developed into treated lesions.

| Patient characteristic | Non-diluted (ND) | Diluted (D) |
|------------------------|-----------------|------------|
| Number of included patients | 112 | 112 |
| Number of females | 50 (44.6%) | 50 (44.6%) |
| Number of males | 62 (55.4%) | 62 (55.4%) |
| Mean age | 54.8 (14.2) | 56.9 (14.1) |
| Mean body mass index (kg/m$^2$) | 25.3 (4.2) | 25.2 (4.4) |
| Liver cirrhosis | 35 (31.3%) | 35 (31.3%) |
| Moderate or severe ascites | 12 (10.7%) | 11 (9.8%) |
| Patients with a liver lesion | 68 (60.7%) | 70 (62.5%) |
| Adenoma | 7 (6.3%) | 6 (5.4%) |
| FNH | 12 (10.7%) | 12 (10.7%) |
| Cirrhotic nodules (LIRADS 3-5) | 20 (17.9%) | 15 (13.4%) |
| Metastases | 23 (20.5%) | 16 (14.3%) |
| Hemangioma | 3 (2.7%) | 3 (2.7%) |
| Treated lesions | 3 (2.7%) | 18 (16.1%) |
less than 1 cm. Because patients with malignant lesions underwent treatment between the MRIs, i.e., resection or ablation, we only compared benign lesions, e.g., FNH, hemangioma, and adenomas < 1 cm. We found 8 such lesions. We were able to detect 5 more lesions and to see 3 lesions better on the diluted vs non-diluted scans. We attribute these findings to TSM artifact reduction as truncation artifacts did not influence the visibility of these lesions.

### Inter-reader agreement

The overall inter-reader agreement measured with the ICC for quantitative SI measurements in the arterial, portal venous, transitional, and HB phases was excellent (0.89). Also, the Cohen’s kappa (κ) coefficient for the visual evaluation of AP artifacts was also similarly high (0.831, \(p < 0.001\)).

### Table 2

detailed results of SI, i.e., the mean SI values of the liver in manually placed ROI calculated from the average reported by readers 1 and 2. Significant differences, \(p < 0.05\), are highlighted in bold. The \(p\) value of comparison by paired \(t\)-test is given. \(PV\) portal vein. \(SD\) standard deviation. \(SI\) signal intensity

|                  | Non-diluted (ND) | Diluted (D) |
|------------------|------------------|-------------|
|                  | Mean SI  | SD   | Mean SI  | SD   | \(p\) value |
| **Unenhanced**   |         |      |         |      |             |
| Liver            | 256.0   | 46.2 | 264.0   | 47.3 | 0.069       |
| Aorta            | 178.0   | 46.2 | 176.2   | 41.4 | 0.679       |
| PV               | 177.4   | 34.3 | 177.1   | 38.9 | 0.939       |
| **Arterial phase** |         |      |         |      |             |
| Liver            | 308.6   | 69.9 | 327.8   | 73.5 | \(0.012\)   |
| Aorta            | 1064.8  | 332.7| 1155.6  | 351.8| \(0.006\)   |
| PV               | 576.2   | 241.5| 576.3   | 249.4| 0.997       |
| **Portal venous phase** |         |      |         |      |             |
| Liver            | 410.2   | 89.7 | 437.2   | 101.6| \(0.002\)   |
| Aorta            | 712.1   | 200.9| 738.1   | 206.7| 0.073       |
| PV               | 773.3   | 204.8| 821.3   | 234.9| \(0.007\)   |
| **Transitional phase** |         |      |         |      |             |
| Liver            | 419.4   | 100.4| 442.4   | 114.4| \(0.019\)   |
| Aorta            | 492.8   | 130.9| 505.6   | 143.0| 0.193       |
| PV               | 500.3   | 121.0| 519.6   | 130.6| 0.094       |
| **Hepatobiliary phase** |         |      |         |      |             |
| Liver            | 452.4   | 105.2| 499.1   | 129.6| \(< 0.001\) |
| Aorta            | 367.2   | 99.7 | 371.4   | 103.2| 0.605       |
| PV               | 366.5   | 88.1 | 371.6   | 93.2 | 0.556       |

### Table 3

detailed results of signal-to-norm (\(S_{INorm}\)), i.e., the mean SI values of the liver divided by the SI of the paraspinal muscle in manually placed ROI calculated from the average reported by readers 1 and 2. Significant differences, \(p < 0.05\), are highlighted in bold. The \(p\) value by paired \(t\)-test is given. \(PV\) portal vein. \(SD\) standard deviation. The \(S_{INorm}\) was calculated for each ROI using the equation:

\[
S_{INorm} = \frac{S_{Iliver}}{S_{Imuscle}}
\]

|                  | Non-diluted (ND) | Diluted (D) |
|------------------|------------------|-------------|
|                  | Mean SI\(_{INorm}\)  | SD   | Mean SI\(_{INorm}\)  | SD   | \(p\) value |
| **Unenhanced**   |         |      |         |      |             |
| Liver            | 1.24   | 0.24 | 1.25   | 0.22 | 0.750       |
| Aorta            | 0.86   | 0.20 | 0.83   | 0.16 | 0.073       |
| PV               | 0.86   | 0.17 | 0.83   | 0.18 | 0.191       |
| **Arterial phase** |         |      |         |      |             |
| Liver            | 1.28   | 0.26 | 1.38   | 0.30 | \(0.002\)   |
| Aorta            | 4.44   | 1.40 | 4.85   | 1.40 | \(0.005\)   |
| PV               | 2.39   | 0.95 | 2.42   | 1.02 | 0.794       |
| **Portal venous phase** |         |      |         |      |             |
| Liver            | 1.63   | 0.30 | 1.71   | 0.37 | \(0.010\)   |
| Aorta            | 2.82   | 0.70 | 2.88   | 0.71 | 0.263       |
| PV               | 3.08   | 0.76 | 3.23   | 0.91 | \(0.035\)   |
| **Transitional phase** |         |      |         |      |             |
| Liver            | 1.63   | 0.32 | 1.66   | 0.40 | 0.364       |
| Aorta            | 1.01   | 0.20 | 1.00   | 0.19 | 0.569       |
| PV               | 1.95   | 0.44 | 1.95   | 0.45 | 0.888       |
| **Hepatobiliary phase** |         |      |         |      |             |
| Liver            | 1.90   | 0.40 | 2.04   | 0.47 | \(< 0.001\) |
| Aorta            | 1.54   | 0.39 | 1.52   | 0.40 | 0.599       |
| PV               | 1.54   | 0.37 | 1.53   | 0.36 | 0.564       |
**Discussion**

Arterial-phase transient severe motion artifacts on gadoxetic acid–enhanced MRI can be mitigated by combined 1:1 saline dilution and slow injection rate of 1 ml/s while preserving or even increasing signal intensity. Furthermore, lesion contrast, indicated by $C_{\text{Norm}}$, was not shown to be inferior on the diluted as compared to the non-diluted exams.

Although both dilution (1:1) and slow injection rate (at 1 ml/s) are off-label use of gadoxetic acid, this combined technique quadruples the time of the arterial phase, allowing k-space more time to achieve homogeneity [20]. Thus, the signal intensity could be higher in comparison to the recommended injection of non-diluted contrast at 2 ml/s.

The reduction of AP artifacts using either dilution or slow injection is already well-recognized. Our findings corroborate those of previous researchers [7, 14–16, 21, 22]. We too postulated that by doubling gadoxetic acid’s mean transit time relative to the short arterial-phase acquisition time, a more favorable bolus configuration was achieved, reducing truncation artifacts which may occur when small volumes, i.e., ≤ 10 ml, of contrast are injected [7, 14, 18, 23–25]. Furthermore,

---

**Table 4** Detailed results of different lesion types using the mean and standard deviation of the $C_{\text{Norm}}$ values, calculated from the average manually placed ROI by readers 1 and 2 in liver, lesion, and paraspinal muscle. PV portal vein. SD standard deviation. $C_{\text{Norm}} = \frac{\text{abs} \; \text{SI}_{\text{liver}} - \text{SI}_{\text{lesion}}}{\text{SI}_{\text{muscle}}}$.

|                  | Non-diluted (ND) | Diluted (D) |
|------------------|------------------|-------------|
|                  | Mean $C_{\text{Norm}}$ | SD | Mean $C_{\text{Norm}}$ | SD | $p$ value |
| Unenhanced       |                  |       |                  |       |          |
| All lesions      | 0.25             | 0.19  | 0.26             | 0.19  | 0.850    |
| FNH              | 0.19             | 0.19  | 0.14             | 0.09  | 0.397    |
| Metastases       | 0.31             | 0.19  | 0.33             | 0.19  | 0.698    |
| Arterial phase   |                  |       |                  |       |          |
| All lesions      | 0.69             | 0.50  | 0.67             | 0.38  | 0.691    |
| FNH              | 1.01             | 0.49  | 0.83             | 0.42  | 0.051    |
| Metastases       | 0.46             | 0.33  | 0.49             | 0.28  | 0.800    |
| Portal venous phase |              |       |                  |       |          |
| All lesions      | 0.53             | 0.39  | 0.59             | 0.40  | 0.357    |
| FNH              | 0.48             | 0.32  | 0.45             | 0.17  | 0.828    |
| Metastases       | 0.63             | 0.49  | 0.63             | 0.43  | 0.999    |
| Transitional phase |                |       |                  |       |          |
| All lesions      | 0.60             | 0.39  | 0.59             | 0.42  | 0.791    |
| FNH              | 0.42             | 0.39  | 0.36             | 0.29  | 0.247    |
| Metastases       | 0.85             | 0.34  | 0.71             | 0.40  | 0.232    |
| Hepatobiliary phase |                |       |                  |       |          |
| All lesions      | 0.94             | 0.56  | 1.01             | 0.62  | 0.207    |
| FNH              | 0.56             | 0.34  | 0.52             | 0.44  | 0.700    |
| Metastases       | 1.35             | 0.34  | 1.38             | 0.39  | 0.817    |
by using parallel imaging, we were able to shorten the acquisition time, making it more similar to the bolus transit time, thus improving k-space homogeneity [26]. AP artifacts were not shown to have a significant influence on SI or SI\text{Norm} of the liver. Therefore, we attribute the higher SI and SI\text{Norm} in the diluted exams to contrast dilution and slower injection rate. Without dilution, AP artifacts have been observed in 10.7–39% of patients [3–6, 10–13]. Polanec et al [7] speculated that this transiently high gadoxetic acid concentration in serum may exceed the threshold, triggering central chemoreceptors, resulting in hyperventilation.

With combined dilution and slow injection, we likely kept peak plasma concentration below the tipping point, avoiding activation of central chemoreceptors that would cause breathhold failure and possibly TSM artifacts. We hypothesized that dilution and slow injection would further lower peak gadoxetic acid plasma concentration, which is already at a dose of 25% that of conventional gadolinium chelates reducing absolute SI, SI\text{Norm}, and C\text{Norm}, potentially decreasing focal liver lesion detection.

Surprisingly, dilution and slow injection did not cause the expected drop in SI in either absolute SI or SI\text{Norm}, and in fact

---

**Fig. 4** a C\text{Norm} FNH. Boxplot graphic of the absolute difference between SI\text{Norm} of FNHs and SI\text{Norm} of the liver, called contrast-to-norm (C\text{Norm}) in all phases. The blue boxes represent exams performed with non-diluted contrast media, the green boxes diluted contrast media. There were no significant differences between the non-diluted and the diluted injection protocol in all phases. b C\text{Norm} metastases. Boxplot graphics of the absolute difference between SI\text{Norm} of metastases and SI\text{Norm} of the liver, called contrast-to-norm (C\text{Norm}) in all phases. The blue boxes represent exams performed with non-diluted contrast media, the green boxes diluted contrast media. There were no significant differences between the non-diluted and the diluted injection protocol in all phases.
increased aortic SI in the AP, portal vein SI in the PVP, and hepatic parenchymal SI in all phases. Furthermore, liver parenchymal SI_{Norm} increased on D versus ND exams in all but the transitional phase. However, once recirculation commenced, with each pass, the D exams maintained their lead on the ND exams which explains why the difference in SI and SI_{Norm} was largest in the HBP, indicating the widening gap between D and ND. Because the half-life of gadoxetic acid is circa 1 h, at this time frame, there is still about 50% of contrast still recirculating [27–29].

This increase in SI_{Norm} in the arterial, portal venous, and hepatobiliary phases on D compared to the ND groups, we attribute to the following factors: dilution, slow injection, and the high relaxivity of gadoxetic acid.

Dilution by doubling the volume, plus slow injection, prolonged the arterial-phase transit time and gave a more uniform shape to the bolus, allowing a more homogeneous intravascular contrast concentration during k-space data sampling [20, 30].

Furthermore, from Zech et al [24], who found higher SNR at 1 ml/s than at 2 ml/s in AP images of pigs injected with gadoxetic acid, we recognize the effect of slow injection. Likewise, Ringe et al [25] among others found that arterial-phase SNR in the aorta and portal vein were exceedingly higher in both slow injection groups, i.e., 1 ml/s ( p < 0.0001 and $p = 0.0016$) [31]. However, neither author analyzed the SI values in the liver parenchyma.

There is a discrepancy between our results and some previous publications, which did not find significant differences in liver SNR between the two protocols, i.e., ND and D exams [15, 32]. However, we attribute our results to the combination of dilution and slow injection, as no previous studies combined both techniques. Furthermore, gadoxetic acid’s relatively high relaxivity in plasma likely explains why SI and SI_{Norm} remained so high, despite the further dilution of its already relatively small per kilogram dose, i.e., 0.025 mmol/kg versus 0.1 mmol/kg dose of gadolinium chelates [23] [33] [32]. Stretching the bolus, by dilution and slow injection, allows more time for protein binding of gadoxetic acid to human plasma. Since the bound fraction of gadoxetic acid has higher relaxivity than the unbound portion, the less compact bolus results in increased relaxivity [32, 33].

Additionally, increasing SI_{Norm} in the HBP is partly due to recirculation of intravascular gadoxetic acid that has not yet gone to the kidney for clearance [34], as the half-life is about 1 h [27–29]. We emphasize that during recirculation, the D exams continue to maintain their advantage over the ND exams, i.e., relatively higher SI_{Norm}. We assume that after the intravascular phase, hepatocyte transporters had more time to accumulate gadoxetic acid due to doubling the volume on the diluted exams.

In general, OATP is a low-affinity but high-capacity carrier for gadoxetic acid [35]. This favors rapid liver enhancement [36]. Because of the bidirectional activity of the OATP transporter, until its decay, any gadoxetic acid not used by the hepatocyte re-enters the intravascular space, giving the remaining gadoxetic acid repeated chances to be taken up by OATP during recirculation [35]. Thus, OATP transporters on the diluted exams had twice as long as the non-diluted group to take up gadoxetic acid, due to the doubled volume caused by saline dilution, and the fact that there is no saturation effect for gadoxetic acid at clinically injected doses [37–40]. Thus, SI_{Norm} could continuously increase, being significantly higher on the D versus ND exams in almost all phases.

Therefore, dilution and slow injection plus shorter scan times seem a very good strategy to mitigate AP artifacts and preserve high-quality imaging [7, 14, 16, 41]. To the best of our knowledge, our study is the first dedicated to elucidating this important issue.

Our study had several limitations. First, it was a retrospective study, with a relatively small cohort and especially few comparable lesions, as the majority of the patients with HCC and metastases underwent treatment leading to a change in the appearance of these lesions between ND and D exams. However, it was sufficient to attain results of statistical significance. Secondly, despite the 5-year interval, we kept all imaging parameters almost constant for both groups.

Second, the fact that we found no significant difference in SI and SI_{Norm} on initial and follow-up unenhanced scans, i.e., our reference images, supports our conclusion that the increase in all phases except transitional was due to dilution and slow injection. Furthermore, even if some parameters, such as FOV, matrix size, and slice thickness, were not constant for the entire cohort as they depend on patient size, they were almost identical for each patient (D vs ND). Therefore, there was no bias since each patient was being compared to himself.

Third, although we initially calculated SNR and CNR, we found extreme outliers since the SD values for air were highly variable throughout the FOV. Furthermore, Dietrich et al [42] have criticized SNR since its calculation for any two ROI on a single image will, in general, not correlate with the true SNR measured on the image after applying certain reconstruction filters, multi-channel reconstruction, or parallel imaging. On the contrary, by using C_{Norm}, we achieved very stable and consistent values that seemed credible, i.e., representative of the actual lesion visibility. The C_{Norm}, like CNR, is an absolute value. It describes the magnitude of the difference between a lesion and the adjacent liver parenchyma without providing information about whether the lesion enhances more or less than the surrounding liver parenchyma after gadoxetic acid injection. In other words, C_{Norm} intuitively provide information about lesion visibility, regardless of whether a focal lesion is hypointense or hyperintense. This enabled an evaluation of the effect of dilution and slow injection on focal liver lesion visibility.

Fourth, the diluted group of patients and technicians were already familiar with the sensation post-gadoxetic acid injection, a potential advantage and bias favoring the diluted vs. non-diluted patients [43]. However, this is a controversial point.
Based upon the literature, Wybranski et al [44] reported that TSM artifacts cannot be mitigated by education and training.

Furthermore, several researchers cite that a previous episode of TSM is a risk factor for another episode of TSM on subsequent gadoxetic acid administration [3, 6, 44, 45].

Next, we used a test bolus injection which is not ideal as it may affect subsequent signal intensity following the intended injection. As we did not have the automatic bolus software, we instead used a 5-s delay for both D and ND groups to estimate peak enhancement, followed by identical scanning parameters for both groups. Choosing the same delay when doubling the injection time was not the optimal protocol. Since we compared each patient to himself for measuring $S_{\text{INorm}}$ differences on D versus ND exams, there was no inherent bias with the test bolus. Even though we may have performed the D group exams too early, the SI values were still higher for D vs ND. It could be speculated that if we had started imaging at t-peak plus 10 s, the SI would probably have been even higher for D.

Lastly, we did not analyze the specific clinical conditions that predisposed patients to AP artifacts. By again comparing each patient to himself, we eliminated the influence of gender, weight, and BMI that can contribute to severe AP artifacts. Nevertheless, due to the retrospective nature of our study, a prospective study, ideally in a larger cohort, is warranted to confirm our findings, especially regarding focal liver lesions.

In conclusion, our results suggest that 1:1 saline dilution of gadoxetic acid, administered at a slowed injection rate of 1 ml/s via a power injector, reduces AP artifacts while increasing $S_{\text{INorm}}$ and preserving $C_{\text{INorm}}$ of images.

**Funding** Open access funding provided by Medical University of Vienna.

**Declarations**

**Guarantor** The scientific guarantor of this publication is Univ.-Prof. Univ.-Doz. Dr. Ahmed Ba-Ssalamah.

**Conflict of interest** Ahmed Ba-Ssalamah has received consultant fees and honorarium for lectures from Bayer.

All other authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

**Statistics and Biometry** Dr. Michael Weber is a professional statistician. He has performed the statistics for this study. He is one of the authors.

michael.weber@meduniwien.ac.at

**Informed Consent** Written informed consent was obtained from all study patients at the time of their MR exams. However, the Institutional Review Board waived written informed consent because of the retrospective nature of our study.

**Ethical Approval** Institutional Review Board approval was obtained.

**Study subjects or cohorts overlap** Thirty of these subjects have been previously used for the following article.

J Magn Reson Imaging 46 (4), 1107-1114 Oct 2017

Respiratory Motion Artifacts During Arterial Phase Imaging with Gadoxetic Acid: Can the Injection Protocol Minimize This Drawback?

Stephan H Polanec, Hubert Bickel, Pascal A T Baltzer, Patrick Thurner, Florian Gittler, Jacqueline C Hodge, Mustafa R Bashir, Ahmed Ba-Ssalamah

**Methodology**

- retrospective
- observational
- performed at one institution

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Ba-Ssalamah A, Uffmann M, Saini S, Bastati N, Herold C, Schima W (2009) Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol 19:342–357

2. Bartolozzi C, Cioni D, Donati F, Lencioni R (2001) Focal liver lesions: MR imaging-pathologic correlation. Eur Radiol 11:1374–1388

3. Bashir MR, Castelli P, Davenport MS et al (2015) Respiratory motion artifact affecting hepatic arterial phase MR imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium. Radiology 274:141–148

4. Davenport MS, Caoili EM, Kaza RK, Hussain HK (2014) Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine. Radiology 272:131–131

5. Bashir MR, Caoili EM, Hussain HK (2014) Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 266:452–461

6. Davenport MS, Bashir MR, Pietryga JA, Weber JT, Khalatbari S, Hussain HK (2014) Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact. AJR Am J Roentgenol 203:796–802

7. Polanec SH, Bickel H, Baltzer PAT et al (2017) Respiratory motion artifacts during arterial phase imaging with gadoxetic acid: can the injection protocol minimize this drawback? J Magn Reson Imaging 46:1107–1114
8. Huang SY, Seethamraju RT, Patel P, Hahn PF, Kirsch JE, Guimaeraes AR (2015) Body MR imaging: artifacts, k-space, and solutions. Radiographics 35:1439–1460
9. Fujinaga Y, Ohya A, Tokoro H et al (2014) Radial volumetric imaging breath-hold examination (VIBE) with k-space weighted image contrast (KWIC) for dynamic gadoteric acid (Gd-EOB-DTPA)-enhanced MRI of the liver: advantages over Cartesian VIBE in the arterial phase. Eur Radiol 24:1290–1299
10. Hong SB, Lee NK, Kim S et al (2019) Modified CAIPIRINHA-VIBE without view-sharing on gadoteric acid-enhanced multi-arterial phase MR imaging for diagnosing hepatocellular carcinoma: comparison with the CAIPIRINHA-Dixon-TWIST-VIBE. Eur Radiol 29:3574–3583
11. Kim YC, Min JH, Kim YK et al (2019) Intra-individual comparison of gadolinium-enhanced MRI using pseudo-golden-angle radial acquisition with gadoteric acid-enhanced MRI for diagnosis of HCCs using LI-RADS. Eur Radiol 29:2058–2068
12. Min JH, Kim YK, Kang TW et al (2018) Artifacts during the arterial phase of gadoteric acid-diluted-enhanced MRI multiple arterial phases using view-sharing from two different vendors versus single arterial phase imaging. Eur Radiol 28:3335–3346
13. Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR (2014) Respiratory motion artifact affecting hepatic arterial phase imaging with gadoteric acid disodium: examination recovery with a multiple arterial phase acquisition. Radiology 271:426–434
14. Kim YK, Lin WC, Sung K et al (2017) Reducing artifacts during arterial phase of gadoteric acid disodium-enhanced MR imaging: dilution method versus reduced injection rate. Radiology 283:429–437
15. Haradome H, Grazioli L, Tsuono M et al (2010) Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoteric acid-DTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? J Magn Reson Imaging 32:334–340
16. Motosugi U, Ichikawa T, Sou H et al (2009) Dilution method of 0.5 mL/s and 1 mL/s injection rates. Korean J Radiol 15:605–612
17. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Zech C (2012) Optimization of the dynamic, Gd-EOB-DTPA-enhanced MRI of the liver: the effect of the injection rate. Acta Radiol 53:961–965
18. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40:715–724
19. Shiroyishi MS, Castellazzi G, Boxerman JL et al (2015) Principles of T2 weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. J Magn Reson Imaging 41:296–313
20. van Montfoort JE, Stieber B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE (1999) Hepatic uptake of the magnetic resonance imaging contrast agent gadoteric acid by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 290:153–157
21. Nassif A, Jia J, Keiser M et al (2012) Visualization of hepatic uptake transporter function in healthy subjects by using gadoteric acid-enhanced MR imaging. Radiology 264:741–750
22. Vogl TJ, Kummer S, Hammerstingl R et al (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200:59–67
23. Hamm B, Staks T, Mueller A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792
24. Schuhmann-Giampieri G, Mahler M, Roll G, Maitbauer R, Schmitz S (1997) Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans. J Clin Pharmacol 37:587–596
25. Huppertz A, Breuer J, Fels LM et al (2011) Evaluation of possible drug-drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATPs). J Magn Reson Imaging 33:409–416
26. Akai H, Yasaka K, Nojima M et al (2018) Gadoteric acid disodium-induced atypical neuropathy and the effect of dilution method: a proof-of-concept study in mice. Eur Radiol 28:692–697
27. Dietrich O, Raya JG, Reeder SB, Reiser MF, Schoenberg SO (2007) Measurement of signal-to-noise ratios in MR images:
influence of multichannel coils, parallel imaging, and reconstruction filters. J Magn Reson Imaging 26:375–385

43. Gutzeit A, Matoori S, Froehlich JM et al (2016) Reduction in respiratory motion artefacts on gadoxetate-enhanced MRI after training technicians to apply a simple and more patient-adapted breathing command. Eur Radiol 26:2714–2722

44. Wybranski C, Siedek F, Damm R et al. (2020) Respiratory motion artefacts in Gd-EOB-DTPA (Primovist/Eovist) and Gd-DOTA (Dotarem)-enhanced dynamic phase liver MRI after intensified and standard pre-scan patient preparation: A bi-institutional analysis. PLoS One 15:e0230024

45. Huh J, Kim SY, Yeh BM et al (2015) Troubleshooting arterial-phase mr images of gadoxetate disodium-enhanced liver. Korean J Radiol 16:1207–1215

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.